SCHEDULE 13D/A: Saba Capital Significantly Reduces Stake in BlackRock Science & Technology Term Trust to 7.02%

Saba Capital Management, L.P. and its affiliates have reduced their beneficial ownership in BlackRock Science & Technology Term Trust to 7.02% through a series of open market sales.

Summary

• Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein (the "Reporting Persons") have filed an Amendment No. 7 to their Schedule 13D regarding BlackRock Science & Technology Term Trust.
• As of February 26, 2025, the Reporting Persons collectively beneficially own 5,078,335 Common Shares of BlackRock Science & Technology Term Trust.
• This ownership represents 7.02% of the issuer's common stock, calculated based on 72,314,687 shares outstanding as of January 15, 2025.
• The total approximate amount paid to acquire the Common Shares reported was $87,303,080.
• Since the previous Schedule 13D/A filing on January 21, 2025, Saba Capital has engaged in open market sales of 1,331,718 Common Shares.
• The sale prices for these transactions ranged from $20.80 to $22.19 per share.
• Funds for the initial purchase of Common Shares were derived from investor subscription proceeds, capital appreciation, and margin account borrowings.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant institutional investor reducing its stake in the company, which can be interpreted as a lack of confidence or a strategic divestment.

Positives

• The Reporting Persons have confirmed they have not been convicted in a criminal proceeding (excluding traffic violations) or been a party to a civil proceeding resulting in a judgment enjoining future violations of federal or state securities laws within the last five years.

Negatives

• Saba Capital, a significant institutional investor, has substantially reduced its stake in BlackRock Science & Technology Term Trust by selling over 1.3 million shares in the open market since January 21, 2025.

Risks

• The reduction in beneficial ownership by a major institutional investor like Saba Capital could be perceived negatively by the market, potentially impacting the issuer's share price.
• The use of margin account borrowings for share acquisition, while common, introduces leverage risk for the Reporting Persons' investment.

Future Outlook

The document does not provide any forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance or strategic direction.

Industry Context

This filing indicates a significant institutional investor, Saba Capital, is reducing its position in a closed-end fund focused on science and technology. While the filing itself doesn't detail broader industry trends, such a reduction by a notable investor could signal a shift in their investment strategy, a re-evaluation of the specific fund's prospects within the technology investment landscape, or a broader trend of profit-taking or rebalancing within the tech sector by large funds.

Stakeholder Impact

• Shareholders: The reduction in stake by a major institutional investor could lead to negative market sentiment and potentially impact the share price. Existing shareholders might interpret this as a signal to re-evaluate their own positions.

Next Steps

• The document does not explicitly mention any future actions, events, or milestones for the issuer or the reporting persons beyond the ongoing management of their investment portfolio.

Key Dates

Recommendation

Keywords

BlackRock Science & Technology Term Trust, Saba Capital Management, Schedule 13D/A, Beneficial Ownership, Institutional Investor, Share Sales, Closed-End Fund, Technology Trust, SEC Filing